BI 1820237
Alternative Names: BI-1820237Latest Information Update: 08 Jul 2024
At a glance
- Originator Boehringer Ingelheim
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 15 Apr 2024 Boehringer Ingelheim initiates a phase I trial for Obesity in Germany (SC) (NCT06352424) (EUCT2023-506233-30-01)
- 08 Apr 2024 Boehringer Ingelheim plans to initiate a phase I trial for Obesity (Monotherapy, In combination therapy) (SC) (NCT06352424)
- 15 Mar 2023 Boehringer Ingelheim initiates a phase I trial in Obesity (In volunteers, Monotherapy) in Germany (SC) ( EudraCT2022-002733-34), NCT05751226)